The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Molecular targeted therapy for advanced gastric cancer

  • Kim, Jong Gwang (Department of Internal Medicine, Kyungpook National University School of Medicine)
  • Published : 2013.03.01
⟨ Previous Next ⟩

Abstract

Although medical treatment has been shown to improve quality of life and prolong survival, no significant progress has been made in the treatment of advanced gastric cancer (AGC) within the last two decades. Thus, the optimum standard first-line chemotherapy regimen for AGC remains debatable, and most responses to chemotherapy are partial and of short duration; the median survival is approximately 7 to 11 months, and survival at 2 years is exceptionally > 10%. Recently, remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways. For AGC, many molecular targeting agents have been evaluated in international randomized studies, and trastuzumab, an anti-HER-2 monoclonal antibody, has shown antitumor activity against HER-2-positive AGC. However, this benefit is limited to only -20% of patients with AGC (patients with HER-2-positive AGC). Therefore, there remains a critical need for both the development of more effective agents and the identification of molecular predictive and prognostic markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies.

Keywords

References

  1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of f luorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  3. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. https://doi.org/10.1056/NEJMoa073149
  4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997. https://doi.org/10.1200/JCO.2006.06.8429
  5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909. https://doi.org/10.1200/JCO.2005.05.0245
  6. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996;2:909-914.
  7. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-4927. https://doi.org/10.1200/JCO.2006.07.1316
  8. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-5875. https://doi.org/10.1158/1078-0432.CCR-06-1970
  9. Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304. https://doi.org/10.1038/sj.bjc.6604861
  10. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517.
  11. Lordick F, Bodoky G, Chung H, et al. Cetuximab in combination with capecitabine and cisplatin as firstline treatment in advanced gastric cancer: randomized controlled phase III EXPAND study [abstract]. Ann Oncol 2012;23:LBA3.
  12. Waddell TS, Chau I, Barbachano Y, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) [abstract]. J Clin Oncol 2012;30:LBA4000. https://doi.org/10.1200/jco.2012.30.18_suppl.lba4000
  13. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-4316. https://doi.org/10.1200/JCO.2005.04.2424
  14. Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gef itinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010;5:229-235. https://doi.org/10.1097/JTO.0b013e3181c5e334
  15. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  16. Iqbal S, Goldman B, Lenz HJ, Fenoglio-Preiser CM, Blanke CD. A phase II study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer [abstract]. J Clin Oncol 2007;25(18 Suppl):4621
  17. Lenz H, Zhang W, Kemner AM. Lapatinib 1 capecitabine in advanced gastric cancer: an open-label phase II study of non ERBB2-targeted disease [abstract]. Ann Oncol 2010;21(Suppl 8):S817.
  18. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206. https://doi.org/10.1200/JCO.2006.08.0887
  19. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-874. https://doi.org/10.1200/JCO.2010.32.0770
  20. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21:1999-2004. https://doi.org/10.1093/annonc/mdq065
  21. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976. https://doi.org/10.1200/JCO.2011.36.2236
  22. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29:1449-1458. https://doi.org/10.1007/s10637-010-9438-y
  23. Moehler M, Mueller A, Hartmann JT, et al. An openlabel, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011;47:1511-1520. https://doi.org/10.1016/j.ejca.2011.04.006
  24. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140. https://doi.org/10.1158/1535-7163.MCT-08-0013
  25. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-2951. https://doi.org/10.1200/JCO.2009.27.7988
  26. Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel antiangiogenic therapy. Future Oncol 2009;5:421-432. https://doi.org/10.2217/fon.09.18
  27. Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus f luoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012;69:439-446. https://doi.org/10.1007/s00280-011-1723-8
  28. Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011;102:1374-1380. https://doi.org/10.1111/j.1349-7006.2011.01939.x
  29. Li J, Qin S, Xu J, et al. A randomized, double-blind, multicenter, phase, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma [abstract]. J Clin Oncol 2011;29(Suppl):4019. https://doi.org/10.1200/jco.2011.29.15_suppl.4019
  30. Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28:1904-1910. https://doi.org/10.1200/JCO.2009.26.2923
  31. Lim T, Lee J, Lee DJ, et al. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 2011;68:255-262. https://doi.org/10.1007/s00280-011-1653-5
  32. Van Cutsem E, Yeh KH, Bang YJ, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012;30(Suppl 4):LBA3. https://doi.org/10.1200/jco.2012.30.4_suppl.lba3
  33. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of cmet and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J
  34. Chang H, Rha SY, Jeung HC, et al. Identif ication of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol 2010;136:1901-1913. https://doi.org/10.1007/s00432-010-0849-0
  35. Parsons SL, Murawa PX, Kolesnik OO, et al. Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study [abstract]. J Clin Oncol 2008;26(Suppl):106. https://doi.org/10.1200/JCO.2007.13.2373

Cited by

  1. The progress of targeted therapy in advanced gastric cancer vol.1, pp.1, 2013, https://doi.org/10.1186/2050-7771-1-32
  2. Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment vol.35, pp.8, 2013, https://doi.org/10.1007/s13277-014-2095-6
  3. Glucose-regulated protein 78 and heparanase expression in oral squamous cell carcinoma: correlations and prognostic significance vol.12, pp.None, 2013, https://doi.org/10.1186/1477-7819-12-121
  4. The microRNA-367 Inhibits the Invasion and Metastasis of Gastric Cancer by Directly Repressing Rab23 vol.19, pp.2, 2013, https://doi.org/10.1089/gtmb.2014.0210
  5. Emerging molecular classifications and therapeutic implications for gastric cancer vol.35, pp.1, 2013, https://doi.org/10.1186/s40880-016-0111-5
  6. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature vol.22, pp.26, 2013, https://doi.org/10.3748/wjg.v22.i26.5896
  7. Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients vol.11, pp.1, 2013, https://doi.org/10.3892/ol.2015.3875
  8. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer vol.37, pp.3, 2013, https://doi.org/10.1007/s13277-015-4144-1
  9. Upregulation of microRNA-31 targeting integrin α5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells vol.37, pp.6, 2013, https://doi.org/10.1007/s13277-015-4511-y
  10. Predictive biomarkers along gastric cancer pathogenetic pathways vol.17, pp.5, 2013, https://doi.org/10.1080/14737140.2017.1301207
  11. From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers—A Multidisciplinary Perspective vol.12, pp.8, 2020, https://doi.org/10.3390/cancers12082105
  12. Beneficial Actions of Orostachys japonica and Its Compounds against Tumors via MAPK Signaling Pathways vol.13, pp.2, 2013, https://doi.org/10.3390/nu13020555